Literature DB >> 23736363

Addiction potential of phentermine prescribed during long-term treatment of obesity.

E J Hendricks1, M Srisurapanont2, S L Schmidt3, M Haggard1, S Souter1, C L Mitchell1, D G De Marco1, M J Hendricks1, Y Istratiy1, F L Greenway4.   

Abstract

OBJECTIVE: To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or phentermine drug craving in overweight, obese and weight loss maintenance patients. To investigate whether amphetamine-like withdrawal occurs after abrupt cessation of long-term phentermine treatment.
DESIGN: Clinical intervention trial with interruption of phentermine treatment in long-term patients.
SUBJECTS: 269 obese, overweight or formerly obese subjects (age: 20-88 years, BMI: 21-74 kg m(-2)) treated with phentermine long-term (LTP, N=117), 1.1-21.1 years, or short-term (ATP, N=152), 4-22 days, with phentermine doses of 18.75-112.5 (LTP) and 15-93.75 (ATP) mg per day. MEASUREMENTS: Module K of the Mini International Neuropsychiatric Interview modified for phentermine (MINI-SUD), Severity of Dependence Scale (SDS), 45-item Cocaine Craving Questionnaire-NOW (CCQ-NOW) modified for phentermine (PCQ-NOW), and Amphetamine Withdrawal Questionnaire (AWQ) modified for phentermine (PWQ).
RESULTS: MINI-SUD interviews were negative for phentermine abuse or psychological dependence in all LTP patients. SDS examination scores were low for all LTP and ATP patients, indicating they were not psychologically dependent upon phentermine. PCQ-NOW scores were low for all LTP and ATP patients, indicating neither short-term nor long-term phentermine treatment had induced phentermine craving. Other than an increase in hunger or eating, amphetamine-like withdrawal symptoms did not occur upon abrupt phentermine cessation as measured by sequential PWQ scores.
CONCLUSIONS: Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity. Phentermine treatment does not induce phentermine drug craving, a hallmark sign of addiction. Amphetamine-like withdrawal does not occur upon abrupt treatment cessation even at doses much higher than commonly recommended and after treatment durations of up to 21 years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23736363     DOI: 10.1038/ijo.2013.74

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  39 in total

1.  Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.

Authors:  Kerri A Schoedel; Carol Addy; Bijan Chakraborty; Kim Rosko; Stephanie Dunbar; Andrea Maes; Nancy Chen; Selwyn Aubrey Stoch; John Wagner; Jeff Chodakewitz; Edward M Sellers
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

2.  Heroin and cocaine craving and use during treatment: measurement validation and potential relationships.

Authors:  Adrienne J Heinz; David H Epstein; Jennifer R Schroeder; Edward G Singleton; Stephen J Heishman; Kenzie L Preston
Journal:  J Subst Abuse Treat       Date:  2006-08-01

Review 3.  Addiction liability of pharmacotherapeutic interventions in obesity.

Authors:  William M Greene; Mark Sylvester; Joel Abraham
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Frequency of use or abuse of amphetamine-related drugs.

Authors:  N C Jain; R D Budd; T C Sneath
Journal:  Am J Drug Alcohol Abuse       Date:  1979       Impact factor: 3.829

5.  Detection of phentermine in hair samples from drug suspects.

Authors:  Sooyeun Lee; Jihyun Kim; Sanghwan In; Hwakyung Choi; Heesun Chung; Kyu Hyuck Chung
Journal:  Forensic Sci Int       Date:  2010-12-03       Impact factor: 2.395

6.  The development of a cocaine craving questionnaire.

Authors:  S T Tiffany; E Singleton; C A Haertzen; J E Henningfield
Journal:  Drug Alcohol Depend       Date:  1993-12       Impact factor: 4.492

7.  Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.

Authors:  Ed J Hendricks; Frank L Greenway; Eric C Westman; Alok K Gupta
Journal:  Obesity (Silver Spring)       Date:  2011-04-28       Impact factor: 5.002

Review 8.  Treatment for amphetamine withdrawal.

Authors:  Steven J Shoptaw; Uyen Kao; Keith Heinzerling; Walter Ling
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

9.  Can the severity of dependence scale be usefully applied to 'ecstasy'?

Authors:  Raimondo Bruno; Allison J Matthews; Libby Topp; Louisa Degenhardt; Rapson Gomez; Matthew Dunn
Journal:  Neuropsychobiology       Date:  2009-11-05       Impact factor: 2.328

Review 10.  Pharmacologic mechanisms of crystal meth.

Authors:  Stephen J Kish
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

View more
  12 in total

1.  Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies.

Authors:  Caroline M Apovian; W Timothy Garvey; Donna H Ryan
Journal:  Obesity (Silver Spring)       Date:  2015-07       Impact factor: 5.002

Review 2.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

3.  How physician obesity medicine specialists treated obesity before 2012 new drug approvals.

Authors:  Stacy L Schmidt; David Bryman; Frank L Greenway; Ed J Hendricks
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

4.  Effect of phentermine on weight reduction in a pediatric weight management clinic.

Authors:  J R Ryder; A Kaizer; K D Rudser; A Gross; A S Kelly; C K Fox
Journal:  Int J Obes (Lond)       Date:  2016-10-24       Impact factor: 5.095

Review 5.  Antiobesity pharmacotherapy: new drugs and emerging targets.

Authors:  G W Kim; J E Lin; E S Blomain; S A Waldman
Journal:  Clin Pharmacol Ther       Date:  2013-10-08       Impact factor: 6.875

Review 6.  New pharmacological treatments for the management of obesity.

Authors:  Ryan T Hurt; Jithinraj Edakkanambeth Varayil; Jon O Ebbert
Journal:  Curr Gastroenterol Rep       Date:  2014

7.  Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard.

Authors:  Christine B San Giovanni; Brooke Sweeney; Joseph A Skelton; Megan M Kelsey; Aaron S Kelly
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

Review 8.  Off-label drugs for weight management.

Authors:  Ed J Hendricks
Journal:  Diabetes Metab Syndr Obes       Date:  2017-06-10       Impact factor: 3.168

Review 9.  Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.

Authors:  Jens Jordan; Arne Astrup; Stefan Engeli; Krzysztof Narkiewicz; Wesley W Day; Nick Finer
Journal:  J Hypertens       Date:  2014-06       Impact factor: 4.844

Review 10.  Weight management in obesity - past and present.

Authors:  D Haslam
Journal:  Int J Clin Pract       Date:  2016-01-26       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.